Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

NCT04262466 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

410

Enrollment

INDUSTRY

Sponsor class

Conditions

Select Advanced Solid Tumors

Interventions

DRUG: Brenetafusp
DRUG: Brenetafusp and pembrolizumab
DRUG: Brenetafusp and chemotherapy
DRUG: Brenetafusp and monoclonal antibodies and chemotherapy
DRUG: Brenetafusp and tebentafusp
DRUG: Brenetafusp and bevacizumab
DRUG: Brenetafusp and kinase inhibitors

Sponsor

Immunocore Ltd